X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4877) 4877
Publication (228) 228
Book Review (58) 58
Book Chapter (31) 31
Magazine Article (28) 28
Book / eBook (17) 17
Conference Proceeding (5) 5
Web Resource (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4296) 4296
female (2418) 2418
male (2299) 2299
index medicus (2293) 2293
middle aged (1682) 1682
hemostatics - therapeutic use (1451) 1451
aged (1396) 1396
surgery (1328) 1328
adult (1214) 1214
treatment outcome (1210) 1210
hemostatics - adverse effects (813) 813
hemostatics - administration & dosage (755) 755
hemostatic techniques (724) 724
cardiac & cardiovascular systems (676) 676
hemostasis (643) 643
animals (617) 617
risk factors (613) 613
peripheral vascular disease (569) 569
retrospective studies (549) 549
hematology (544) 544
prospective studies (536) 536
aged, 80 and over (532) 532
hemostatic techniques - instrumentation (515) 515
blood loss, surgical - prevention & control (492) 492
time factors (477) 477
hemorrhage (470) 470
hemorrhage - etiology (459) 459
hemostatic techniques - adverse effects (422) 422
hemorrhage - prevention & control (405) 405
hemostatics (399) 399
management (392) 392
adolescent (386) 386
complications (371) 371
thrombin (302) 302
postoperative hemorrhage - prevention & control (300) 300
analysis (291) 291
abridged index medicus (289) 289
blood transfusion (287) 287
child (286) 286
coagulation (285) 285
medicine & public health (285) 285
health aspects (269) 269
cardiopulmonary bypass (267) 267
aprotinin - therapeutic use (264) 264
follow-up studies (263) 263
young adult (263) 263
equipment design (259) 259
postoperative hemorrhage - etiology (259) 259
care and treatment (251) 251
bleeding (250) 250
hemostatics - pharmacology (246) 246
risk assessment (235) 235
anesthesiology (234) 234
hemostasis, surgical - methods (234) 234
hemorrhage - therapy (231) 231
mortality (230) 230
efficacy (228) 228
safety (221) 221
therapy (217) 217
punctures (215) 215
blood (214) 214
anticoagulants - adverse effects (213) 213
aprotinin - adverse effects (212) 212
respiratory system (212) 212
cardiac-surgery (208) 208
transfusion (208) 208
child, preschool (203) 203
gastroenterology & hepatology (203) 203
risk (203) 203
medicine, general & internal (201) 201
fibrin (199) 199
femoral artery (198) 198
recombinant proteins - therapeutic use (193) 193
radiology, nuclear medicine & medical imaging (186) 186
thrombosis (185) 185
cardiac catheterization - adverse effects (183) 183
blood coagulation - drug effects (182) 182
trial (182) 182
hemorrhage - drug therapy (178) 178
double-blind method (177) 177
tranexamic acid (172) 172
anticoagulants (170) 170
anticoagulants - therapeutic use (169) 169
blood-loss (166) 166
plasma (165) 165
patients (163) 163
fibrinogen (162) 162
aprotinin (158) 158
obstetrics & gynecology (157) 157
pharmacology & pharmacy (155) 155
activated factor-vii (154) 154
catheterization, peripheral - adverse effects (153) 153
pregnancy (153) 153
thrombin - administration & dosage (153) 153
pressure (152) 152
usage (151) 151
clinical neurology (150) 150
factor viia - therapeutic use (150) 150
infant (148) 148
trauma (147) 147
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4644) 4644
French (83) 83
German (63) 63
Russian (34) 34
Spanish (27) 27
Chinese (21) 21
Japanese (21) 21
Italian (16) 16
Polish (13) 13
Danish (7) 7
Hungarian (5) 5
Dutch (4) 4
Norwegian (4) 4
Portuguese (3) 3
Serbian (3) 3
Turkish (3) 3
Bulgarian (2) 2
Croatian (2) 2
Czech (2) 2
Arabic (1) 1
Bosnian (1) 1
Finnish (1) 1
Icelandic (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Urology and Nephrology, ISSN 0301-1623, 9/2017, Volume 49, Issue 9, pp. 1519 - 1526
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Circulation, ISSN 0009-7322, 09/2013, Volume 128, Issue 11, pp. 1234 - 1243
BACKGROUND—Patients experiencing major bleeding while taking vitamin K antagonists require rapid vitamin K antagonist reversal. We performed a prospective... 
CARDIAC & CARDIOVASCULAR SYSTEMS | ORAL ANTICOAGULANT REVERSAL | CLINICAL-TRIAL | RECOMBINANT FACTOR-VIII | vitamin K antagonist | prothrombin complex concentrates | PREVIOUSLY UNTREATED PATIENTS | INTRACRANIAL HEMORRHAGE | THERAPY | WARFARIN | TRANSFUSION | HEMOPHILIA-A | anticoagulants | PERIPHERAL VASCULAR DISEASE | plasma | FRESH-FROZEN PLASMA | hemorrhage | Single-Blind Method | Plasma | Prospective Studies | Thromboembolism - chemically induced | Factor IX - therapeutic use | Humans | Middle Aged | Male | Factor IX - adverse effects | Hemorrhage - prevention & control | Vitamin K - antagonists & inhibitors | Thromboembolism - prevention & control | Aged, 80 and over | Adult | Factor X - therapeutic use | Female | Factor X - adverse effects | Factor VII - adverse effects | Factor VII - therapeutic use | Emergencies | Anticoagulants - therapeutic use | Treatment Outcome | Prothrombin - therapeutic use | Anticoagulants - adverse effects | Prothrombin - adverse effects | Hemostatics - adverse effects | International Normalized Ratio | Hemorrhage - drug therapy | Blood Coagulation Factors - adverse effects | Anticoagulants - pharmacology | Blood Coagulation Factors - therapeutic use | Aged | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Drug Combinations | Antidotes - therapeutic use | Antagonists (Biochemistry) | Usage | Care and treatment | Blood coagulation factors | Health aspects | Hemorrhage
Journal Article
Gastrointestinal Endoscopy, ISSN 0016-5107, 2012, Volume 76, Issue 4, pp. 707 - 718
Journal Article
European Heart Journal, ISSN 0195-668X, 02/2013, Volume 34, Issue 7, pp. 489 - 500
Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently available for prevention of venous... 
Novel oral anticoagulants | Bleeding | Management | RECOMBINANT FACTOR-VIIA | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | RANDOMIZED EVALUATION | INTRACRANIAL HEMORRHAGE | ACTIVATED FACTOR-VII | FACTOR-XA INHIBITOR | DABIGATRAN ETEXILATE | VENOUS THROMBOEMBOLISM | PROTHROMBIN COMPLEX CONCENTRATE | NONVALVULAR ATRIAL-FIBRILLATION | Plasma | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Antithrombins - administration & dosage | Hemorrhage - prevention & control | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | beta-Alanine - pharmacology | Renal Insufficiency - complications | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Acute Disease | beta-Alanine - adverse effects | Administration, Oral | Morpholines - administration & dosage | Risk Factors | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Anticoagulants - pharmacology | Antithrombins - adverse effects | Blood Coagulation Tests | Benzimidazoles - pharmacology | Aged | Hemostatics - therapeutic use | Pyridones - adverse effects | Pyridones - pharmacology | Renal Dialysis
Journal Article
Journal Article
Archives of Cardiovascular Diseases, ISSN 1875-2136, 2013, Volume 106, Issue 6, pp. 382 - 393
Summary Direct new oral anticoagulants (NOACs) – inhibitors of thrombin or factor Xa – are intended to be used largely in the treatment of venous... 
Cardiovascular | Internal Medicine | Réversion | Hémorragie | Surgery | Reversal | Chirurgie | Anti-Xa | Bleeding | Anti-IIa | CARDIAC & CARDIOVASCULAR SYSTEMS | ASSAYS LABORATORY RECOMMENDATIONS | RIVAROXABAN | PHARMACODYNAMICS | COAGULATION ASSAYS | ATRIAL-FIBRILLATION | DABIGATRAN ETEXILATE | PHARMACOKINETICS | WARFARIN | PROTHROMBIN COMPLEX CONCENTRATE | Anti-lla | Perioperative Care | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Postoperative Hemorrhage - diagnosis | Postoperative Hemorrhage - chemically induced | Antithrombins - administration & dosage | Dabigatran | Drug Monitoring - methods | Rivaroxaban | Time Factors | Patient Safety | Benzimidazoles - adverse effects | Postoperative Hemorrhage - therapy | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Surgical Procedures, Operative - adverse effects | beta-Alanine - adverse effects | Drug Administration Schedule | Risk Assessment | Administration, Oral | Hemorrhage - therapy | Risk Factors | Emergencies | Treatment Outcome | Anticoagulants - adverse effects | Anticoagulants - blood | Hemorrhage - diagnosis | Coagulants - therapeutic use | Blood Coagulation - drug effects | Hemostatic Techniques | Antithrombins - adverse effects | Antithrombins - blood | Blood Coagulation Tests | Hemorrhage - chemically induced | Coagulants - adverse effects
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 04/2008, Volume 6, Issue 4, pp. 622 - 631
Journal Article
Journal of Vascular and Interventional Radiology, ISSN 1051-0443, 2012, Volume 23, Issue 6, pp. 727 - 736
Journal Article